Ginkgo Bioworks Holdings, Inc. — Form 8-K Summary
Business context and reporting period
Ginkgo Bioworks Holdings, Inc. filed this Form 8-K on February 29, 2024, under Items 2.02 and 9.01. The filing announces the release of financial results for the fourth quarter and fiscal year ended December 31, 2023. The referenced earnings press release was furnished as Exhibit 99.1, but its contents are not included in the provided filing text.
Financial metrics
The provided filing text does not provide clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, operating expenses, or other financial metrics. Investors should review Exhibit 99.1 and the related annual filing for these amounts.
Material changes versus the prior comparable period
The filing text does not describe year-over-year or quarter-over-quarter changes. No comparative financial data is provided in the supplied text.
Guidance, outlook, risks, contingencies, and unusual items
The filing text does not provide guidance, an outlook, management commentary, risk updates, contingencies, or unusual-item disclosures. Any such information may be contained in the omitted Exhibit 99.1.
Key facts to verify
- Obtain and review Exhibit 99.1 for fourth-quarter and full-year 2023 financial results.
- Verify revenue, profitability, cash flow, cash and equivalents, liquidity, debt, and margin figures.
- Review management’s guidance, outlook, operating metrics, and discussion of risks or unusual items.
- Compare the reported results with the fourth quarter and full year of 2022.
- Confirm any non-GAAP measures and reconcile them to the applicable GAAP measures.